Skip to main
SGMT

SGMT Stock Forecast & Price Target

SGMT Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 57%
Buy 29%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Sagimet Biosciences is a promising company with strong financial backing and potential in the dermatology market. With a focus on developing therapies for MASH and acne, they have shown positive results in their ongoing Phase 3 trial for denifanstat and are confident in the potential success of their drug TVB-3567 in their Phase 1 trial. Their innovative approach to targeting dysfunctional metabolic and fibrotic pathways in diseases sets them apart in the biopharmaceutical industry.

Bears say

Sagimet Biosciences is facing many challenges as they pivot from developing a drug for fatty liver disease to an acne treatment, resulting in a negative outlook for their stock. Analysts have updated their models to reflect a shift in focus from MASH to acne, leading to a decrease in peak sales projections. Additionally, the company's cash flow is now heavily relied upon by investors to fund the development of their pipeline, creating an uncertain financial future.

SGMT has been analyzed by 7 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 29% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sagimet Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sagimet Biosciences Inc (SGMT) Forecast

Analysts have given SGMT a Buy based on their latest research and market trends.

According to 7 analysts, SGMT has a Buy consensus rating as of Jun 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sagimet Biosciences Inc (SGMT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.